Publication | Closed Access

Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study

Solid TumorsMedicineImmunologyImmune Checkpoint InhibitorCancer TreatmentImmunotherapyOncologyRadiation OncologyMulticenter Phase 1BChemotherapyMonoclonal Antibody